Engineer binders to intercept a single protein-protein interface, leaving the remaining functions of your target intact. Cell-validated and computationally designed—no pocket required.
Your target has five functional domains. You need to study one. A genetic knockout eliminates them all, making precise biological attribution impossible.
Your interface has no grooves, no pockets, and no druggable features. Years of high-throughput small-molecule screening returned nothing.
A highly reproducible milestone framework tailored to your program's specific binding parameters. Progress is measured by data generation, not arbitrary timelines.
Partners securely upload structural files via our air-gapped intake portal. The ProxAI engine maps the exact geometric coordinates and uncovers hidden interaction hotspots on flat surfaces.
Our deep learning models generate over 100,000 completely de novo candidate sequences custom-tailored to bind exclusively with the identified hotspot geometry.
The library shifts to physical cell systems. Using automated multi-parameter FACS tracking, we screen millions of cellular variants in real-time, pulling out elite binders.
Top binder assets undergo meticulous characterization, and cross-reactive safety assays to ensure absolute specificity. Access data through our secured portal.
Not catalog-first. Target-first.
Four chassis, chosen strictly on the merits of your binding interface.
Fab / scFv designs with established manufacturing and regulatory precedent.
Single-domain VHH framework with camelid-derived loop flexibility.
De novo scaffolds offering high stability and precise interface targeting.
Constrained macrocycles with cell permeability and oral bioavailability potential.
Bypassing manual, low-throughput structural verification. We translate digital sequence libraries into dense, physical assay matrices to fish out elite binders at unmatched scale.
Digital sequence outputs from our engine are compiled into physical high-density oligo pools. Every de novo candidate is tagged with a unique, traceable molecular DNA barcode.
Barcoded libraries are cloned directly into expression vectors. Host cell systems process the library, displaying thousands of custom-engineered binder chassis simultaneously across the living membrane.
Fluorescence-Activated Cell Sorting profiles cellular bindings at high velocity (up to 70k events/sec). Binders are partitioned dynamically based on precise affinity thresholds and strict off-target cross-reactivity boundaries.
Sorted high-affinity cells undergo deep Next-Generation Sequencing. The molecular barcodes are decrypted to map the exact chemical structures and output a complete biophysical hit package.
Exploiting native cellular regulation mechanisms. We engineer high-precision binders to execute two completely distinct therapeutic modalities.
Direct, high-affinity competitive disruption of targeted protein-protein interaction interfaces. Our binders act as physical shields, shutting down down-stream oncogenic signaling across traditionally undruggable flat surfaces.
Bifunctional chimera systems that hijack native cell biology. By mechanically cross-linking your target straight to intracellular degradation machineries, we achieve complete catalytic elimination of the target protein.
Real-time performance metrics from the ProxAI Engine. From sequence design to Validated Lead in < 12 weeks.
Comparing AI-Fold to Ground Truth
Engineered by pioneers at the intersection of generative deep learning and cell biology. Backed by industry-leading clinical translational expertise.
Chief Executive Officer
Architect of the ProxAI generative engine. Computational cell biologist specializing in Protein-Protein interactions and proteomics data analysis.
Chief Scientific Officer
Pioneer in protein degradation and immunology. Leads the high-throughput experimental validation loop for all in-house modalities.
Scientific & Business Advisor
Guides late-stage lead optimization and IND-enabling strategies. Provides business guidance.
Scientific Advisor
Full professor at the University of Montreal. Leader in immunology and Parkinson's disease research.
Scientific Advisor
President and Scientific Director at the IRCM. Full professor at the University of Montreal. Leader in interactomics and oncology research.
Scientific & Business Advisor
Guides late-stage lead optimization and IND-enabling strategies for induced proximity targets.
Business Advisor
Seasoned leader with broad experience across strategy, marketing, talent management, and operational roles within the digital health, biotech, and pharmaceutical industries.
Scientific & Business Advisor
Seasoned biotech entrepreneur with 30+ years founding, scaling, and commercializing innovative life science technologies. Leader in industrialization and market launches.
Flexible, value-aligned alignment structures built for global pharma and emerging biotech discovery pipelines.
Partner provides the therapeutic target structure; ProxAI delivers cell-validated lead candidate packages. Shared risk, milestone-driven structures optimized for rapid pipeline expansion.
Enterprise access to the ProxAI structural generation engine. Deploy our pre-trained generative networks directly inside your internal compute clusters to power scaled multi-target campaigns.
Your structural target data never enters public models. Every partnership campaign runs inside an isolated, air-gapped container environment.
Connect with our business development and scientific advisory teams. Submit your details below to schedule an exploratory briefing and initiate mutual NDAs.
